Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31692117 | 0.95 | TOP1 (0.76) | TOP1SLC2A1 | |
| SCHEMBL25082767 | 0.95 | TOP1 (0.76) | TOP1SLC2A1 | |
| SCHEMBL23196106 | 0.95 | TOP1 (0.80) | TOP1SLC2A1 | |
| SCHEMBL21450505 | 0.93 | TOP1 (0.78) | TOP1SLC2A1 | |
| SCHEMBL26293227 | 0.92 | TOP1 (0.81) | TOP1SLC2A1 | |
| SCHEMBL21450507 | 0.92 | TOP1 (0.75) | TOP1SLC2A1 | |
| SCHEMBL21450354 | 0.91 | TOP1 (0.73) | TOP1SLC2A1 | |
| SCHEMBL21450516 | 0.90 | TOP1 (0.85) | TOP1SLC2A1 | |
| SCHEMBL25404251 | 0.90 | TOP1 (0.66) | TOP1 | |
| SCHEMBL9563389 | 0.90 | TOP1 (0.76) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4389752-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023020605-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 江苏先声药业有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2019195665-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPCAM, TOP2A, SPAG5 | TOP1 4/4885SLC2A1 1660/4885 |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | TOP1 4/4885SLC2A1 3489/4885 |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | TOP1 4/4885SLC2A1 3489/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | TOP1 9/4885SLC2A1 3318/4885 |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | TOP1 9/4885SLC2A1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.